These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 36780114)
1. Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study. Chiriboga CA; Bruno C; Duong T; Fischer D; Mercuri E; Kirschner J; Kostera-Pruszczyk A; Jaber B; Gorni K; Kletzl H; Carruthers I; Martin C; Warren F; Scalco RS; Wagner KR; Muntoni F; Neurol Ther; 2023 Apr; 12(2):543-557. PubMed ID: 36780114 [TBL] [Abstract][Full Text] [Related]
2. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Chiriboga CA; Bruno C; Duong T; Fischer D; Mercuri E; Kirschner J; Kostera-Pruszczyk A; Jaber B; Gorni K; Kletzl H; Carruthers I; Martin C; Scalco RS; Fontoura P; Muntoni F; J Neurol; 2024 Aug; 271(8):4871-4884. PubMed ID: 38733387 [TBL] [Abstract][Full Text] [Related]
3. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany. Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T; Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272 [TBL] [Abstract][Full Text] [Related]
4. [Risdiplam for the treatment of spinal muscular atrophy]. Vlodavets DV Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810 [TBL] [Abstract][Full Text] [Related]
5. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis. Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305 [TBL] [Abstract][Full Text] [Related]
6. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain. Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G; J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761 [TBL] [Abstract][Full Text] [Related]
7. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study. Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087 [TBL] [Abstract][Full Text] [Related]
9. Safety of risdiplam in spinal muscular atrophy patients after short-term treatment with nusinersen. Yan Y; Feng Y; Jiang L; Jin J; Mao S Muscle Nerve; 2024 Nov; 70(5):1095-1098. PubMed ID: 39136364 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Mercuri E; Deconinck N; Mazzone ES; Nascimento A; Oskoui M; Saito K; Vuillerot C; Baranello G; Boespflug-Tanguy O; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Staunton H; Yeung WY; Martin C; Fontoura P; Day JW; Lancet Neurol; 2022 Jan; 21(1):42-52. PubMed ID: 34942136 [TBL] [Abstract][Full Text] [Related]
11. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT; Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364 [TBL] [Abstract][Full Text] [Related]
13. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam. Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185 [TBL] [Abstract][Full Text] [Related]
14. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693 [No Abstract] [Full Text] [Related]
15. An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. Kwon JM; Arya K; Kuntz N; Phan HC; Sieburg C; Swoboda KJ; Veerapandiyan A; Assman B; Bader-Weder S; Dickendesher TL; Hansen J; Lin H; Yan Y; Rao VK; Ann Clin Transl Neurol; 2022 Jun; 9(6):810-818. PubMed ID: 35567422 [TBL] [Abstract][Full Text] [Related]
16. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB; Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373 [TBL] [Abstract][Full Text] [Related]
17. Risdiplam in Type 1 Spinal Muscular Atrophy. Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L; N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251 [TBL] [Abstract][Full Text] [Related]
18. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). Markati T; Fisher G; Ramdas S; Servais L Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil. Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723 [TBL] [Abstract][Full Text] [Related]
20. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L; N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]